In:
Cytometry Part A, Wiley, Vol. 103, No. 2 ( 2023-02), p. 153-161
Abstract:
We evaluated the number of CD26 expressing cells in peripheral blood of patients with COVID‐19 within 72 h of admission and on day 4 and day 7 after enrollment. The majority of CD26 expressing cells were presented by CD3 + CD4 + lymphocytes. A low number of CD26 expressing cells were found to be associated with critical‐severity COVID‐19 disease. Conversely, increasing numbers of CD26 expressing T cells over the first week of standard treatment was associated with good outcomes. Clinically, the number of circulating CD26 cells might be a marker of recovery or the therapeutic efficacy of anti‐COVID‐19 treatment. New therapies aimed at preserving and increasing the level of CD26 expressing T cells may prove useful in the treatment of COVID‐19 disease.
Type of Medium:
Online Resource
ISSN:
1552-4922
,
1552-4930
DOI:
10.1002/cyto.a.24547
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2180639-1
SSG:
12